Covered recipient · General Payments record
JOHN C BROWNING
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$16,155.84
102 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,216.00 | 4 |
| Consulting Fee | $2,450.00 | 1 |
| Food and Beverage | $1,792.35 | 95 |
| Travel and Lodging | $617.50 | 1 |
| Education | $79.99 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $11,543.85 | 10 |
| Eli Lilly and Company | $2,450.00 | 1 |
| AbbVie Inc. | $617.52 | 23 |
| Novartis Pharmaceuticals Corporation | $544.86 | 5 |
| Janssen Biotech, Inc. | $277.77 | 12 |
| LEO Pharma Inc. | $152.83 | 13 |
| Lilly USA, LLC | $107.01 | 8 |
| GENZYME CORPORATION | $103.85 | 5 |
| PFIZER INC. | $92.47 | 10 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $83.84 | 5 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $60.15 | 4 |
| Pierre Fabre Pharmaceuticals, Inc. | $52.16 | 2 |
| Genentech USA, Inc. | $34.79 | 2 |
| Kyowa Kirin, Inc. | $17.93 | 1 |
| Incyte Corporation | $16.81 | 1 |
Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN C BROWNING
NPI 1124181615 · CMS profile ID 142316
Allopathic & Osteopathic Physicians / Dermatology
SAN ANTONIO, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1124181615?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN C BROWNING, NPI 1124181615, CMS profile ID 142316. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124181615?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). JOHN C BROWNING, NPI 1124181615, CMS profile ID 142316. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124181615?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- JOHN C BROWNING, NPI 1124181615, CMS profile ID 142316, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1124181615?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
102 matching records · $16,155.84 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 102.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $121.17 | 07/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809562469 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $14.77 | 07/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849555897 | CMS |
| Regeneron Healthcare Solutions, Inc. | $11.66 | 07/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809562467 | CMS |
| LEO Pharma Inc. | $11.44 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842151207 | CMS |
| AbbVie Inc. | $0.69 | 07/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794169019 | CMS |
| Lilly USA, LLC | $13.71 | 07/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818570663 | CMS |
| AbbVie Inc. | $18.17 | 07/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794169015 | CMS |
| Janssen Biotech, Inc. | $7.30 | 07/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787876511 | CMS |
| Novartis Pharmaceuticals Corporation | $16.86 | 06/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812620333 | CMS |
| Lilly USA, LLC | $14.91 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818571441 | CMS |
| PFIZER INC. | $16.34 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832502043 | CMS |
| LEO Pharma Inc. | $15.97 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842151193 | CMS |
| GENZYME CORPORATION | $23.64 | 06/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843609761 | CMS |
| AbbVie Inc. | $15.02 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794169011 | CMS |
| Janssen Biotech, Inc. | $7.50 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787876495 | CMS |
| Regeneron Healthcare Solutions, Inc. | $11.31 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809562465 | CMS |
| LEO Pharma Inc. | $2.56 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842151163 | CMS |
| LEO Pharma Inc. | $10.74 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842151175 | CMS |
| AbbVie Inc. | $23.42 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794169007 | CMS |
| Genentech USA, Inc. | $12.68 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835927941 | CMS |
| LEO Pharma Inc. | $10.77 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842151147 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $13.32 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849555895 | CMS |
| AbbVie Inc. | $21.42 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794169003 | CMS |
| AbbVie Inc. | $23.08 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794168999 | CMS |
| Lilly USA, LLC | $8.68 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819157323 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $14.89 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851893333 | CMS |
| GENZYME CORPORATION | $16.36 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843609735 | CMS |
| LEO Pharma Inc. | $14.51 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842151129 | CMS |
| Pierre Fabre Pharmaceuticals, Inc. | $26.95 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 854637709 | CMS |
| PFIZER INC. | $8.23 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833288561 | CMS |
| Regeneron Healthcare Solutions, Inc. | $18.48 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809562463 | CMS |
| AbbVie Inc. | $28.59 | 04/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794168995 | CMS |
| Novartis Pharmaceuticals Corporation | $480.00 | 04/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812620325 | CMS |
| Novartis Pharmaceuticals Corporation | $11.86 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812620327 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $18.33 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851893335 | CMS |
| LEO Pharma Inc. | $13.05 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842151111 | CMS |
| Lilly USA, LLC | $5.80 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819157319 | CMS |
| PFIZER INC. | $17.23 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832501353 | CMS |
| Janssen Biotech, Inc. | $16.34 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787876527 | CMS |
| AbbVie Inc. | $19.03 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794168991 | CMS |
| PFIZER INC. | $9.56 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833288455 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $16.95 | 03/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849555893 | CMS |
| Novartis Pharmaceuticals Corporation | $16.97 | 03/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812620331 | CMS |
| AbbVie Inc. | $23.29 | 03/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794168987 | CMS |
| AbbVie Inc. | $15.33 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794168983 | CMS |
| Janssen Biotech, Inc. | $22.19 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787876489 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,760.00 | 02/18/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809562461 | CMS |
| Kyowa Kirin, Inc. | $17.93 | 02/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852982653 | CMS |
| AbbVie Inc. | $24.86 | 02/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794168979 | CMS |
| GENZYME CORPORATION | $22.66 | 02/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843609719 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,160.14 | 7 |
| PY2025 | Principal investigator | $2,082,447.74 | 329 |
| PY2024 | Recipient | $12,422.58 | 3 |
| PY2024 | Principal investigator | $1,724,395.97 | 752 |
| PY2023 | Recipient | $5,832.00 | 1 |
| PY2023 | Principal investigator | $1,177,285.76 | 612 |
| PY2022 | Recipient | $8,234.10 | 5 |
| PY2022 | Principal investigator | $692,813.32 | 90 |
| PY2021 | Recipient | $6,272.50 | 7 |
| PY2021 | Principal investigator | $1,053,264.90 | 82 |
| PY2020 | Recipient | $1,123.60 | 3 |
| PY2020 | Principal investigator | $1,431,344.77 | 107 |
| PY2019 | Recipient | $18,929.61 | 8 |
| PY2019 | Principal investigator | $2,232,845.85 | 131 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
336 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $1,665.00 | 12/25/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372692 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,476.25 | 12/24/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435047 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $763.65 | 12/22/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1226085853 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,073.00 | 12/22/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085855 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $2,000.00 | 12/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234517794 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $150.00 | 12/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234517797 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $3,554.92 | 12/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234517801 |
| Principal investigator 1 | Incyte Corporation | $195.84 | 12/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598313 |
| Principal investigator 1 | Incyte Corporation | $204.00 | 12/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598317 |
| Principal investigator 1 | Incyte Corporation | $354.00 | 12/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598325 |
| Principal investigator 1 | Incyte Corporation | $911.20 | 12/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598329 |
| Principal investigator 1 | Incyte Corporation | $6,600.00 | 12/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598334 |
| Principal investigator 1 | Incyte Corporation | $653.76 | 12/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598337 |
| Principal investigator 1 | Incyte Corporation | $1,875.00 | 12/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598340 |
| Principal investigator 1 | Incyte Corporation | $1,713.60 | 12/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598472 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,465.50 | 12/18/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435029 |
| Principal investigator 1 | PFIZER INC. | $1,839.82 | 12/17/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228733115 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $23,091.54 | 12/17/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289794 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $2,392.00 | 12/16/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163814 |
| Principal investigator 1 | Incyte Corporation | $6,789.60 | 12/11/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598310 |
| Principal investigator 1 | PFIZER INC. | $4,614.29 | 12/11/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228733807 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $31,510.92 | 12/10/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289498 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,206.50 | 12/08/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226086003 |
| Principal investigator 1 | ABBVIE INC. | $14,195.28 | 12/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202529094 |
| Principal investigator 1 | ABBVIE INC. | $7,811.55 | 12/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202529096 |
| Principal investigator 1 | Incyte Corporation | $9,061.50 | 12/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598303 |
| Principal investigator 1 | Incyte Corporation | $14,068.20 | 12/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598306 |
| Principal investigator 1 | Incyte Corporation | $1,037.70 | 12/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598320 |
| Principal investigator 1 | Incyte Corporation | $10,727.70 | 12/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598465 |
| Principal investigator 1 | Incyte Corporation | $4,897.80 | 12/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,646.11 | 12/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184269609 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,167.83 | 12/04/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435043 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,665.00 | 12/01/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372555 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,217.00 | 12/01/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175372656 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,370.96 | 12/01/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289089 |
| Principal investigator 1 | Eli Lilly and Company | $11,221.00 | 11/25/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | No dispute reported | 06/30/2026 | 1187891618 |
| Principal investigator 1 | Incyte Corporation | $1,676.70 | 11/25/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598454 |
| Principal investigator 1 | PFIZER INC. | $1,755.34 | 11/25/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228738729 |
| Principal investigator 1 | Incyte Corporation | $1,713.60 | 11/20/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598457 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,550.00 | 11/17/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372662 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,280.20 | 11/17/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1226085995 |
| Principal investigator 1 | Incyte Corporation | $936.90 | 11/14/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598299 |
| Principal investigator 1 | Incyte Corporation | $1,676.70 | 11/14/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598461 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6,508.35 | 11/13/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435018 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $31,355.00 | 11/10/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085999 |
| Principal investigator 1 | Incyte Corporation | $2,008.80 | 11/07/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598293 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,403.86 | 11/07/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184258095 |
| Principal investigator 1 | ABBVIE INC. | $13,446.84 | 11/05/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202521377 |
| Principal investigator 1 | ABBVIE INC. | $5,098.95 | 11/05/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202521379 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,724.00 | 11/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372530 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $33,488.46 | 11/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287871 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,862.00 | 10/31/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175372600 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $8,961.29 | 10/30/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Specialists | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235993331 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $34.80 | 10/29/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234517353 |
| Principal investigator 1 | Incyte Corporation | $1,676.70 | 10/29/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598445 |
| Principal investigator 1 | PFIZER INC. | $20,986.38 | 10/29/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228741525 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,766.00 | 10/24/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372626 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,785.28 | 10/23/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184252878 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $10,416.60 | 10/23/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435021 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,616.98 | 10/23/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435025 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,547.98 | 10/22/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287311 |
| Principal investigator 1 | Eli Lilly and Company | $49,924.00 | 10/21/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187890848 |
| Principal investigator 1 | Incyte Corporation | $3,507.30 | 10/16/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598441 |
| Principal investigator 1 | Eli Lilly and Company | $8,920.00 | 10/14/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187891270 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,951.00 | 10/14/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085982 |
| Principal investigator 1 | ABBVIE INC. | $6,967.80 | 10/09/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202515799 |
| Principal investigator 1 | ABBVIE INC. | $18,696.05 | 10/09/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202515801 |
| Principal investigator 1 | Incyte Corporation | $2,854.80 | 10/09/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598289 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9,709.20 | 10/09/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435011 |
| Principal investigator 1 | Incyte Corporation | $3,394.80 | 10/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598284 |
| Principal investigator 1 | Incyte Corporation | $4,814.10 | 10/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598450 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,064.03 | 10/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184244921 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $24,860.70 | 10/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286323 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,816.32 | 10/01/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286103 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,081.54 | 10/01/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223286145 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,045.00 | 09/29/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175372545 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,665.00 | 09/29/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372702 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $480.00 | 09/24/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234516837 |
| Principal investigator 1 | PFIZER INC. | $9,833.00 | 09/24/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A LONGTERM DOUBLEBLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031 | No dispute reported | 06/30/2026 | 1228757761 |
| Principal investigator 1 | Incyte Corporation | $2,114.10 | 09/23/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598271 |
| Principal investigator 1 | Incyte Corporation | $3,137.40 | 09/23/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598428 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,048.40 | 09/22/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085978 |
| Principal investigator 1 | Incyte Corporation | $3,137.40 | 09/18/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598433 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,239.00 | 09/16/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175284709 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 09/16/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175284915 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,368.00 | 09/16/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175285859 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,875.00 | 09/15/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085975 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $2,769.00 | 09/12/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163812 |
| Principal investigator 1 | Incyte Corporation | $4,383.00 | 09/12/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598275 |
| Principal investigator 1 | Incyte Corporation | $4,814.10 | 09/12/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598437 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,826.00 | 09/08/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372684 |
| Principal investigator 1 | ABBVIE INC. | $10,706.40 | 09/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202509604 |
| Principal investigator 1 | ABBVIE INC. | $11,029.25 | 09/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202509606 |
| Principal investigator 1 | Incyte Corporation | $3,186.00 | 09/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598279 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,447.00 | 09/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175372561 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,474.08 | 09/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284889 |
| Principal investigator 1 | Incyte Corporation | $2,114.10 | 08/26/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598254 |
| Principal investigator 1 | Incyte Corporation | $4,295.00 | 08/26/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598425 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,513.00 | 08/25/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372609 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,048.40 | 08/25/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085971 |
| Principal investigator 1 | Incyte Corporation | $1,071.90 | 08/21/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598258 |
| Principal investigator 1 | Incyte Corporation | $4,608.00 | 08/21/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598421 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,432.47 | 08/21/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184229867 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9,377.78 | 08/20/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435040 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,233.96 | 08/19/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435005 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,245.00 | 08/18/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085962 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,469.32 | 08/15/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284343 |
| Principal investigator 1 | Incyte Corporation | $2,768.40 | 08/14/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598266 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,605.15 | 08/13/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435002 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,011.23 | 08/12/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246434996 |
| Principal investigator 1 | Incyte Corporation | $2,523.60 | 08/07/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598262 |
| Principal investigator 1 | Incyte Corporation | $2,941.20 | 08/07/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598417 |
| Principal investigator 1 | ABBVIE INC. | $21,677.85 | 08/06/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202503461 |
| Principal investigator 1 | ABBVIE INC. | $19,115.08 | 08/06/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202503567 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,513.00 | 08/01/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372584 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,599.54 | 08/01/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283367 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,861.24 | 08/01/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283369 |
| Principal investigator 1 | Incyte Corporation | $3,132.00 | 07/31/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598401 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $339.15 | 07/31/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184223040 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,496.00 | 07/28/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372573 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,201.00 | 07/28/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175372589 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,802.40 | 07/28/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085958 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,755.00 | 07/23/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283012 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,800.00 | 07/23/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283014 |
| Principal investigator 1 | Incyte Corporation | $3,680.10 | 07/22/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598397 |
| Principal investigator 1 | Eli Lilly and Company | $5,244.56 | 07/17/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) | No dispute reported | 06/30/2026 | 1187890280 |
| Principal investigator 1 | Incyte Corporation | $624.60 | 07/17/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598246 |
| Principal investigator 1 | Incyte Corporation | $4,295.00 | 07/17/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598405 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $436.05 | 07/17/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184217358 |
| Principal investigator 1 | Galderma Laboratories, L.P. | $6,495.50 | 07/16/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1234515311 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $24,775.00 | 07/14/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085954 |
| Principal investigator 1 | Incyte Corporation | $10,301.40 | 07/10/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598250 |
| Principal investigator 1 | Incyte Corporation | $1,470.60 | 07/10/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598413 |
| Principal investigator 1 | PFIZER INC. | $12,435.00 | 07/09/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228771771 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,572.82 | 07/09/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223282456 |
| Principal investigator 1 | Incyte Corporation | $1,830.60 | 07/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598409 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $726.75 | 07/04/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184213123 |
| Principal investigator 1 | ABBVIE INC. | $8,811.00 | 07/02/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202496515 |
| Principal investigator 1 | ABBVIE INC. | $2,689.35 | 07/02/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202496517 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,780.30 | 07/02/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085946 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,377.00 | 07/02/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226085950 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,534.00 | 06/26/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175372567 |
| Principal investigator 1 | Incyte Corporation | $3,102.30 | 06/24/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598232 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,423.83 | 06/24/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190307249 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $6,500.00 | 06/23/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis | No dispute reported | 06/30/2026 | 1248163810 |
| Principal investigator 1 | Incyte Corporation | $15,053.40 | 06/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598237 |
| Principal investigator 1 | Incyte Corporation | $3,661.20 | 06/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598387 |
| Principal investigator 1 | ABBVIE INC. | $4,383.66 | 06/18/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | No dispute reported | 06/30/2026 | 1202492127 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $23,633.00 | 06/16/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085932 |
| Principal investigator 1 | Incyte Corporation | $643.50 | 06/12/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598392 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20,167.32 | 06/06/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280940 |
| Principal investigator 1 | Incyte Corporation | $2,187.00 | 06/05/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598241 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.38 | 06/05/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184204455 |
| Principal investigator 1 | ABBVIE INC. | $4,993.65 | 06/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202487839 |
| Principal investigator 1 | ABBVIE INC. | $1,919.30 | 06/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202488027 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,299.88 | 05/30/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435037 |
| Principal investigator 1 | Incyte Corporation | $4,496.40 | 05/28/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598220 |
| Principal investigator 1 | Incyte Corporation | $3,507.30 | 05/28/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598378 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,635.23 | 05/28/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184199103 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 05/28/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280442 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,398.00 | 05/26/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372633 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,862.00 | 05/22/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175372538 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,292.54 | 05/21/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280068 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,729.00 | 05/19/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226085938 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $26,076.00 | 05/19/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085943 |
| Principal investigator 1 | Incyte Corporation | $2,333.70 | 05/15/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598228 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,530.52 | 05/13/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190304339 |
| Principal investigator 1 | Incyte Corporation | $2,456.10 | 05/08/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598225 |
| Principal investigator 1 | Incyte Corporation | $1,676.70 | 05/08/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598382 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,409.24 | 05/08/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184193873 |
| Principal investigator 1 | ABBVIE INC. | $22,522.50 | 05/07/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202483001 |
| Principal investigator 1 | ABBVIE INC. | $2,589.17 | 05/07/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202483003 |
| Principal investigator 1 | PFIZER INC. | $291.00 | 05/06/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228781607 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,218.40 | 05/05/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085915 |
| Principal investigator 1 | Incyte Corporation | $28,103.40 | 04/28/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598217 |
| Principal investigator 1 | Incyte Corporation | $1,676.70 | 04/28/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598358 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,310.00 | 04/28/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285278 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,220.00 | 04/28/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175372709 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,300.00 | 04/28/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurigo Nodularis | No dispute reported | 06/30/2026 | 1226085927 |
| Principal investigator 1 | Eli Lilly and Company | $4,994.13 | 04/23/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | No dispute reported | 06/30/2026 | 1187890528 |
| Principal investigator 1 | Incyte Corporation | $3,353.40 | 04/23/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598362 |
| Principal investigator 1 | Incyte Corporation | $5,341.50 | 04/15/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598372 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,162.80 | 04/15/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184183234 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,490.00 | 04/14/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085920 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,539.60 | 04/14/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226085922 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,175.80 | 04/14/2025 | Non-covered Recipient Entity Revival Research Institute, Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226126601 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $42.40 | 04/14/2025 | Non-covered Recipient Entity Revival Research Institute, Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226126605 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,648.20 | 04/11/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278034 |
| Principal investigator 1 | Incyte Corporation | $28,384.20 | 04/08/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598366 |
| Principal investigator 1 | ABBVIE INC. | $2,116.40 | 04/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202472492 |
| Principal investigator 1 | ABBVIE INC. | $12,559.95 | 04/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202473050 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,121.10 | 04/02/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226085911 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,733.00 | 03/27/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175372618 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,118.00 | 03/24/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372650 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,238.60 | 03/24/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226085904 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $39,396.00 | 03/24/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085908 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $436.05 | 03/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184174322 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,000.00 | 03/17/2025 | Non-covered Recipient Entity Revival Research Institute, Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226126442 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,288.00 | 03/17/2025 | Non-covered Recipient Entity Revival Research Institute, Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226126446 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,112.48 | 03/11/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184170720 |
| Principal investigator 1 | Eli Lilly and Company | $2,070.57 | 03/10/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187890850 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,947.10 | 03/10/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226085900 |
| Principal investigator 1 | ABBVIE INC. | $13,694.85 | 03/07/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202460257 |
| Principal investigator 1 | ABBVIE INC. | $4,232.80 | 03/07/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202460261 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,545.22 | 03/05/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276029 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,477.00 | 03/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175372641 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,344.88 | 03/03/2025 | Non-covered Recipient Entity Texas Dermatology and Laser Specialists | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435032 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,466.00 | 02/27/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285739 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,310.00 | 02/27/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285939 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,953.44 | 02/26/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275647 |
| Principal investigator 1 | Eli Lilly and Company | $1,072.78 | 02/25/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187890524 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $387.60 | 02/25/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155574 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $27,556.10 | 02/24/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226085888 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,375.00 | 02/24/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226085897 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $22,906.60 | 02/24/2025 | Non-covered Recipient Entity Revival Research Institute, Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226126449 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $18.99 | 02/21/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184115905 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,068.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284025 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,974.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284033 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,518.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284048 |
| Principal investigator 1 | Janssen Research & Development, LLC | $156.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284077 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284088 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,068.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284101 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,974.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284106 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284139 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,068.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284154 |
| Principal investigator 1 | Janssen Research & Development, LLC | $156.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284177 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284206 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284241 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284255 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284280 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,518.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284346 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284390 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,068.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284408 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284456 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284474 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284481 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,974.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284499 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284524 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284532 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284582 |
| Principal investigator 1 | Janssen Research & Development, LLC | $156.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284627 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284660 |
| Principal investigator 1 | Janssen Research & Development, LLC | $156.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284683 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284704 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,974.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284726 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,500.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284780 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284803 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,974.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284818 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284843 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,974.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284860 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284884 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284890 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284907 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175284988 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,974.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285002 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285018 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285025 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285034 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,974.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285079 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285186 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285193 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285215 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,518.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285224 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285270 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,518.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285285 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,974.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285309 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,974.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285335 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285342 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285348 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285390 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285397 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285422 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285450 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285494 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,068.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285501 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,068.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285584 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285652 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285709 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,974.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285731 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285756 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285800 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,044.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285814 |
| Principal investigator 1 | Janssen Research & Development, LLC | $156.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285849 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,518.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285888 |
| Principal investigator 1 | Janssen Research & Development, LLC | $205.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285894 |
| Principal investigator 1 | Janssen Research & Development, LLC | $574.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285919 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285927 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285967 |
| Principal investigator 1 | Janssen Research & Development, LLC | $156.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285974 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285981 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,143.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285987 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,518.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285993 |
| Principal investigator 1 | Janssen Research & Development, LLC | $156.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175286003 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175286010 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175286020 |
| Principal investigator 1 | Janssen Research & Development, LLC | $156.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175286030 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,516.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175286036 |
| Principal investigator 1 | Janssen Research & Development, LLC | $218.00 | 02/19/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175286044 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $57.36 | 02/19/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | Pediatric Study in children with moderate to severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1190304341 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $724.88 | 02/18/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184154572 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,300.00 | 02/18/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085884 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,174.04 | 02/14/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Specialists | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | No dispute reported | 06/30/2026 | 1235993333 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,095.19 | 02/11/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184153136 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,003.00 | 02/07/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175372675 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $325.47 | 02/07/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184115895 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $68.89 | 02/07/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184115897 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $30.01 | 02/07/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184115899 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $96.17 | 02/07/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184115901 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $62.01 | 02/07/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184115903 |
| Principal investigator 1 | ABBVIE INC. | $21,084.30 | 02/06/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202447215 |
| Principal investigator 1 | ABBVIE INC. | $12,911.14 | 02/06/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202447219 |
| Principal investigator 1 | Incyte Corporation | $624.60 | 02/05/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598355 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $23,649.06 | 02/05/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274861 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,028.00 | 02/04/2025 | Non-covered Recipient Entity Texas Dermatology And Laser Special | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226085893 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,849.82 | 02/03/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274685 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $558.60 | 01/31/2025 | Covered Recipient Physician | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) | No dispute reported | 06/30/2026 | 1184115893 |
| Principal investigator 1 | Incyte Corporation | $2,499.30 | 01/29/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598351 |
| Principal investigator 1 | Amgen Inc. | $53,177.06 | 01/27/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246649181 |
| Principal investigator 1 | Eli Lilly and Company | $942.96 | 01/27/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187892956 |
| Principal investigator 1 | Eli Lilly and Company | $5,029.95 | 01/27/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187893106 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,228.00 | 01/27/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175285563 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,180.00 | 01/27/2025 | Non-covered Recipient Entity Revival Research Institute, Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226126430 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $540.00 | 01/27/2025 | Non-covered Recipient Entity Revival Research Institute, Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226126434 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,000.00 | 01/27/2025 | Non-covered Recipient Entity Revival Research Institute, Inc | Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226126437 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,451.00 | 01/24/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIAL ISTS | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175372595 |
| Principal investigator 1 | Eli Lilly and Company | $62,695.00 | 01/22/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187890466 |
| Principal investigator 1 | Eli Lilly and Company | $10,928.00 | 01/22/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187892092 |
| Principal investigator 1 | Eli Lilly and Company | $96,438.00 | 01/22/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187892094 |
| Principal investigator 1 | Incyte Corporation | $1,561.50 | 01/17/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598344 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $484.50 | 01/17/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184148305 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,084.00 | 01/16/2025 | Non-covered Recipient Entity Tx Derm and Laser Specialists | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175285117 |
| Principal investigator 1 | Eli Lilly and Company | $104,731.90 | 01/07/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187890530 |
| Principal investigator 1 | Incyte Corporation | $4,797.90 | 01/07/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240598348 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $920.55 | 01/07/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184146114 |
| Principal investigator 1 | ABBVIE INC. | $420.00 | 01/02/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER | M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) | No dispute reported | 06/30/2026 | 1202433789 |
| Principal investigator 1 | Amgen Inc. | $4,978.96 | 01/02/2025 | Non-covered Recipient Entity TEXAS DERMATOLOGY AND LASER SPECIALISTS | A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) | No dispute reported | 06/30/2026 | 1246649186 |